Short-term effects of PCSK-9 inhibitors on percutaneous coronary intervention in patients with acute coronary syndrome
{{output}}
Background/aims: Proprotein-converting enzyme subtilisin-kexin type 9 (PCSK9) inhibitors act more promptly and efficiently than statins and reduce the risk of cardiovascular events in patients with acute coronary syndrome (ACS). ... ...
